share_log

Scotiabank Initiates Coverage On NewAmsterdam Pharma With Sector Outperform Rating, Announces Price Target of $35

Scotiabank Initiates Coverage On NewAmsterdam Pharma With Sector Outperform Rating, Announces Price Target of $35

丰业银行以行业跑赢大盘的评级启动对新阿姆斯特丹制药公司的报道,宣布目标股价为35美元
Moomoo 24/7 ·  03/13 17:22

Scotiabank analyst George Farmer initiates coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Sector Outperform rating and announces Price Target of $35.

丰业银行分析师乔治·法默以行业跑赢大盘的评级启动了对新阿姆斯特丹制药公司(纳斯达克股票代码:NAMS)的报道,并宣布目标股价为35美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发